RECOVERY: COVID-19 Kaletra

In patients admitted to hospital with COVID-19, does Lopinavir-ritonavir therapy (Kaletra) compared to usual care, reduce 28-day mortality?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
In patients admitted to hospital with COVID-19, does Lopinavir-ritonavir therapy (Kaletra) compared to usual care, reduce 28-day mortality?
Continue reading »In hospitalised adult patients with evidence of lower respiratory tract infection due to COVID-19, is remdesivir superior to placebo in shortening the time to recovery?
Continue reading »A multicentre evaluation of two intensive care unit triage protocols for use in an influenza pandemic Winston K Cheung. Medical Journal of Australia; August 2012 [3]:178-181. doi:10.5694/mja11.10926] Clinical Question In the event of a viral pandemic, what effect does the use of a triage protocol (specifically the NSW ICU triage protocol) have in increasing ICU bed availability, both in admission […]
Continue reading »In patients with severe sepsis what is the sensitivity of blood cultures taken after the initiation of antimicrobial therapy?
Continue reading »Is 5-day oral lefamulin non-inferior to 7-day oral moxifloxacin in the management of community-acquired bacterial pneumonia?
Continue reading »Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest Francois et al. N Engl J Med 2019;381:1831-42. DOI: 10.1056/NEJMoa1812379 Clinical Question In post out-of-hospital cardiac arrest patients treated with targeted temperature management, does the use of empirical antibiotics prevent early ventilator-associated pneumonia? Background Rates of survival to hospital discharge and good neurological outcomes post out-of-hospital cardiac arrest (OOHCA) remain poor Despite […]
Continue reading »Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum Beta-lactamase-producing enterobacteriaceae in Dutch hospitals Kluytmans-van den Bergh. Lancet Infectious Diseases 2019; Published online 23rd August 2019. doi: 10.1016/S1473-3099(19)30262-2. Clinical Question In non-ICU, non-haematology patients that have been identified as carriers of extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLs), is a strategy of contact precautions in a multiple-bed room compared to contact […]
Continue reading »In patients with necrotising soft tissue infection (NSTI), does the use of intravenous immunoglobulin (IVIG) compared to placebo improve patient reported physical outcomes?
Continue reading »In non-neutropenic critically ill patients with sepsis, multiple Candida colonisation, and multiple organ failure exposed to broad-spectrum antibacterials, does empirical micafungin therapy compared to placebo increase invasive fungal infection-free survival at day 28?
Continue reading »In patients with drained cutaneous abscesses does trimethoprim-sulfamethoxazole compared with placebo increase clinical cure rates?
Continue reading »